Marksans Pharma Ltd.

NSE: MARKSANS | BSE: 524404 | ISIN: INE750C01026 | Industry: Pharmaceuticals
| Mid-range Performer
249.9500 -3.40 (-1.34%)
NSE Jun 10, 2025 15:31 PM
Volume: 716.8K
 

249.95
-1.34%
Karvy
Marksans consolidated revenue up by 32.2% YoY and PAT up by 37.6% YoY in nine months of FY15. EBITDA margins at 23.35% for the 9 month period have grown at 50.8% YoY and a PAT growth at 13.5%. The company's US formulations segment reported revenue growth at 81.3% and reported revenues of Rs.120 crore for the nine month period
Marksans Pharma Ltd. has lost -24.68% in the last 6 Months
More from Marksans Pharma Ltd.
Recommended